Gilead’s Kite Pharma has snagged an option to buy gamma delta T-cell receptor (TCR) startup Gadeta. The deal sees Kite take a stake in Gadeta and commit to milestones tied to the progress of oncology candidates.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,